However, the mechanisms of its anti‐tumor activity also include effects on immune responses and direct effects against cells that establish tumors.27 In recent years, as PD‐1, CTLA4, and other immune checkpoint inhibitors have played increasingly important roles in anti‐tumor therapies, immune responses have become a focus of increasingly serious interest. The gene discussed is CTLA4; the disease is neoplasm.